| abstract |
The invention relates to a pharmaceutical composition comprising, as a active principle, human antibodies of IgG isotype, neutralizing the activity of a human cytokine selected from VEGF, IFN.alpha. l ~ IL-4, TNF.alpha., and TGF.beta., said neutralizing antibodies inhibiting less than 50% of the maximum biological activity induced by an amount 0.006 ng to 0.05 ng of said cytokine in vitro. |